Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz

Table 3 Responder variables, weeks 18 and 26 (per-protocol set)

Visit (week)	Artz	Durolane	Odds ratio (95%CI)
Visit (week)	(5 × 2.5 ml)	(1 × 3 ml, 4 × sham)	Odds ratio (95%CI)
	( n = 158)	( n = 161)	P value
OMERACT-OARSI
Week 18
Responder	146 (92.4%)	152 (94.4%)	1.15 (0.63; 2.09)
Nonresponder	12 (7.6%)	9 (5.6%)	0.6487
Week 26
Responder	148 (93.7%)	151 (93.8%)	1.12 (0.61; 2.05)
Nonresponder	10 (6.3%)	10 (6.2%)	0.7129
WOMAC pain subscale
Week 18
Responder	116 (73.4%)	124 (77.0%)	0.91 (0.62; 1.35)
Nonresponder	42 (26.6%)	37 (23.0%)	0.6473
Week 26
Responder	129 (81.6%)	127 (78.9%)	0.96 (0.65; 1.41)
Nonresponder	29 (18.4%)	34 (21.1%)	0.8157
WOMAC pain ‘walking on a flat surface’ item
Week 18
Responder	152 (96.2%)	149 (92.5%)	2.12 (1.14; 3.94)
Nonresponder	6 (3.8%)	12 (7.5%)	0.0176
Week 26
Responder	153 (96.8%)	148 (91.9%)	2.26 (1.23; 4.12)
Nonresponder	5 (3.2%)	13 (8.1%)	0.0082

Data presented as n (%). Odds ratio obtained from a generalized estimable equation model. Durolane from Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). CI, confidence interval; OMERACT-OARSI, Outcome Measures in Rheumatoid Arthritis Clinical Trials – Osteoarthritis Research Society International; WOMAC, Western Ontario and McMaster University.

ISSN: 1478-6362